Promising results for new quality of vision metric

Article

It is mandatory to develop precise , reproducible and accurate methodologies to obtain objective measurements of quality of vision, namely night vision, in order to create surgical techniques that will eliminate post-refractive vision disturbances, Joachim Murta said.

It is mandatory to develop precise , reproducible and accurate methodologies to obtain objective measurements of quality of vision, namely night vision, in order to create surgical techniques that will eliminate post-refractive vision disturbances, Joachim Murta said.

He added that a study conducted with a new quality of vision metric showed promising results.

Dr Murta of the University Hospital Coimbra, Portugal, performed a prospective study to evaluate the quality of vision in patients undergoing LASIK with either Planoscan or Zyoptix, using a new methodology called Mesopic High Resolution Perimetry. "It uses a frequency doubling technique which is relatively independent of optical factors," said Dr Murta.

The study evaluated contrast sensitivity in patients submitted to LASIK. Mesopic High Resolution Perimetry analysed central vision, while a Optical Quality Analysis System (OQAS) tested peripheral vision.

40 eyes with less than 6 D of myopia and 1.5 D of astigmatism were included. Group I were treated with Planoscan while Group II were treated with Zyoptix. Pre- and postoperative spherical equivalent, mean keratometry, age, OZ, RST, pupil size, aberrometry and subjective rating of night vision complaints were evaluated.

A decreased contrast sensitivity was noted in myopes compared with normal population (p

Dr Murta concluded that the preliminary results obtained are promising for the evaluation of the quality of vision under mesopic conditions.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.